A case of Inoperable Chemotherapy-resistant Pleural Mesothelioma Treated with Subcutaneous Administration of Inactivated Sendai Virus Particles (HVJ-E) and Concurrent Chemotherapy for the First Time after the HVJ-E P-I Trial

We have previously conducted a P-I clinical trial using inactivated Sendai virus particles (HVJ-E: Hemagglutinating virus of Japan envelope), which have anti-tumor immune activation and direct anti-tumor activity in patients with inoperable chemotherapy-resistant malignant pleural mesothelioma (MPM). We report on the first experience of a patient enrolled in this clinical trial who was treated with continuous subcutaneous administration of HVJ-E with another chemotherapy regimen at the same time. After PD evaluation in the preceding P-I clinical trial, the patient started chemotherapy with gemcitabine and CPT-11 and received subcutaneous HVJ-E. HVJ-E has been used in the past as a single reagent for pleural mesothelioma, melanoma, and prostate cancer in the past as clinical studies and P-I clinical trials. This was the first time that HVJ-E was administered in combination with chemotherapy, and no serious adverse events were observed that could be caused by HVJ-E or chemotherapy were observed in that time. We have reported a valuable case that will be useful in combining HVJ-E with other treatments in the future, as we report the details of this case.